StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Isentress / Isentress HD (raltegravir by Quarter

Isentress / Isentress HD (raltegravir — HIV-1 integrase inhibitor) — U.S. sales ($M) ($M)

QuarterlyAnnual

Merck Isentress / Isentress HD (raltegravir: $36M in Q2 2026, down 25.0% from a year earlier.

Latest, Q2 2026
36
Period ended Jun 30, 2026
Change on a year earlier
-25.0%
48 in Q2 2025
History
38 quarters
Since Q1 2017
Sources
34
Documents cited below

Where the Q2 2026 figure comes from

“|| Isentress/Isentress HD | 60 | 86 | -30 | 36 | 48 | -26 | 24 | 38 | -36”

Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗

Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedIsentress / Isentress HD (raltegravir — HIV-1 integrase inhibitor) — U.S. sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 202636-25.0%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 202635-31.4%Form 10-Q (filed 2026-05-04) ↗
Q4 2025Dec 31, 202537-2.6%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2025Sep 30, 202544-18.5%Form 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗
Q2 2025Jun 30, 202548+11.6%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2025Mar 31, 202551+2.0%Form 8-K (tm2512885d1_ex99-1.htm, filed 2025-04-24) ↗
Q4 2024Dec 31, 202438-24.0%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2024Sep 30, 202454-6.9%Form 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗
Q2 2024Jun 30, 202443-23.2%Form 8-K (tm2521736d1_ex99-1.htm, filed 2025-07-29) ↗
Q1 2024Mar 31, 202450-3.8%Form 8-K (tm2512885d1_ex99-1.htm, filed 2025-04-24) ↗
Q4 2023Dec 31, 202350-35.9%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q3 2023Sep 30, 202358-14.7%Form 8-K (tm2426878d1_ex99-1.htm, filed 2024-10-31) ↗
Q2 2023Jun 30, 202356-16.4%Form 8-K (tm2420272d1_ex99-1.htm, filed 2024-07-30) ↗
Q1 2023Mar 31, 202352-14.8%Form 8-K (tm2412490d1_ex99-1.htm, filed 2024-04-25) ↗
Q4 2022Dec 31, 202278+8.3%Form 10-K (filed 2025-02-25) ↗
Q3 2022Sep 30, 202268-11.7%Form 10-Q (filed 2023-11-03) ↗

Breakdown

What makes up isentress / Isentress HD (raltegravir

Cite this data

StockData. (2026). Merck Isentress / Isentress HD (raltegravir ($M), quarterly Q1 2017–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-isentress-us

See every metric in the Merck KPI table. Data updated Oct 26, 2026.